288 related articles for article (PubMed ID: 23233360)
1. CD22 ligation inhibits downstream B cell receptor signaling and Ca(2+) flux upon activation.
Sieger N; Fleischer SJ; Mei HE; Reiter K; Shock A; Burmester GR; Daridon C; Dörner T
Arthritis Rheum; 2013 Mar; 65(3):770-9. PubMed ID: 23233360
[TBL] [Abstract][Full Text] [Related]
2. Extensive crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in human lymphoma cells.
Chang CH; Wang Y; Gupta P; Goldenberg DM
MAbs; 2015; 7(1):199-211. PubMed ID: 25484043
[TBL] [Abstract][Full Text] [Related]
3. Targeting CD22 with the monoclonal antibody epratuzumab modulates human B-cell maturation and cytokine production in response to Toll-like receptor 7 (TLR7) and B-cell receptor (BCR) signaling.
Giltiay NV; Shu GL; Shock A; Clark EA
Arthritis Res Ther; 2017 May; 19(1):91. PubMed ID: 28506291
[TBL] [Abstract][Full Text] [Related]
4. Epratuzumab modulates B-cell signaling without affecting B-cell numbers or B-cell functions in a mouse model with humanized CD22.
Özgör L; Brandl C; Shock A; Nitschke L
Eur J Immunol; 2016 Sep; 46(9):2260-72. PubMed ID: 27352780
[TBL] [Abstract][Full Text] [Related]
5. Enhanced Tyrosine Phosphatase Activity Underlies Dysregulated B Cell Receptor Signaling and Promotes Survival of Human Lupus B Cells.
Fleischer SJ; Daridon C; Fleischer V; Lipsky PE; Dörner T
Arthritis Rheumatol; 2016 May; 68(5):1210-21. PubMed ID: 26713408
[TBL] [Abstract][Full Text] [Related]
6. CD22 and autoimmune disease.
Dörner T; Shock A; Smith KG
Int Rev Immunol; 2012 Oct; 31(5):363-78. PubMed ID: 23083346
[TBL] [Abstract][Full Text] [Related]
7. The mechanistic impact of CD22 engagement with epratuzumab on B cell function: Implications for the treatment of systemic lupus erythematosus.
Dörner T; Shock A; Goldenberg DM; Lipsky PE
Autoimmun Rev; 2015 Dec; 14(12):1079-86. PubMed ID: 26212727
[TBL] [Abstract][Full Text] [Related]
8. Epratuzumab inhibits the production of the proinflammatory cytokines IL-6 and TNF-α, but not the regulatory cytokine IL-10, by B cells from healthy donors and SLE patients.
Fleischer V; Sieber J; Fleischer SJ; Shock A; Heine G; Daridon C; Dörner T
Arthritis Res Ther; 2015 Jul; 17(1):185. PubMed ID: 26183319
[TBL] [Abstract][Full Text] [Related]
9. CD19 amplification of B lymphocyte Ca2+ responses: a role for Lyn sequestration in extinguishing negative regulation.
Fujimoto M; Poe JC; Hasegawa M; Tedder TF
J Biol Chem; 2001 Nov; 276(48):44820-7. PubMed ID: 11584010
[TBL] [Abstract][Full Text] [Related]
10. Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus.
Daridon C; Blassfeld D; Reiter K; Mei HE; Giesecke C; Goldenberg DM; Hansen A; Hostmann A; Frölich D; Dörner T
Arthritis Res Ther; 2010; 12(6):R204. PubMed ID: 21050432
[TBL] [Abstract][Full Text] [Related]
11. Trogocytosis of multiple B-cell surface markers by CD22 targeting with epratuzumab.
Rossi EA; Goldenberg DM; Michel R; Rossi DL; Wallace DJ; Chang CH
Blood; 2013 Oct; 122(17):3020-9. PubMed ID: 23821660
[TBL] [Abstract][Full Text] [Related]
12. Novel binding site for Src homology 2-containing protein-tyrosine phosphatase-1 in CD22 activated by B lymphocyte stimulation with antigen.
Zhu C; Sato M; Yanagisawa T; Fujimoto M; Adachi T; Tsubata T
J Biol Chem; 2008 Jan; 283(3):1653-1659. PubMed ID: 18024433
[TBL] [Abstract][Full Text] [Related]
13. Swiprosin-1/EFhd2 controls B cell receptor signaling through the assembly of the B cell receptor, Syk, and phospholipase C gamma2 in membrane rafts.
Kroczek C; Lang C; Brachs S; Grohmann M; Dütting S; Schweizer A; Nitschke L; Feller SM; Jäck HM; Mielenz D
J Immunol; 2010 Apr; 184(7):3665-76. PubMed ID: 20194721
[TBL] [Abstract][Full Text] [Related]
14. Regulation of MHC class II signal transduction by the B cell coreceptors CD19 and CD22.
Bobbitt KR; Justement LB
J Immunol; 2000 Nov; 165(10):5588-96. PubMed ID: 11067914
[TBL] [Abstract][Full Text] [Related]
15. Besides an ITIM/SHP-1-dependent pathway, CD22 collaborates with Grb2 and plasma membrane calcium-ATPase in an ITIM/SHP-1-independent pathway of attenuation of Ca2+i signal in B cells.
Chen J; Wang H; Xu WP; Wei SS; Li HJ; Mei YQ; Li YG; Wang YP
Oncotarget; 2016 Aug; 7(35):56129-56146. PubMed ID: 27276708
[TBL] [Abstract][Full Text] [Related]
16. Defective negative regulation of antigen receptor signaling in Lyn-deficient B lymphocytes.
Chan VW; Lowell CA; DeFranco AL
Curr Biol; 1998 May; 8(10):545-53. PubMed ID: 9601638
[TBL] [Abstract][Full Text] [Related]
17. CD22 cross-linking generates B-cell antigen receptor-independent signals that activate the JNK/SAPK signaling cascade.
Tuscano JM; Riva A; Toscano SN; Tedder TF; Kehrl JH
Blood; 1999 Aug; 94(4):1382-92. PubMed ID: 10438726
[TBL] [Abstract][Full Text] [Related]
18. CD22-Binding Synthetic Sialosides Regulate B Lymphocyte Proliferation Through CD22 Ligand-Dependent and Independent Pathways, and Enhance Antibody Production in Mice.
Matsubara N; Imamura A; Yonemizu T; Akatsu C; Yang H; Ueki A; Watanabe N; Abdu-Allah H; Numoto N; Takematsu H; Kitazume S; Tedder TF; Marth JD; Ito N; Ando H; Ishida H; Kiso M; Tsubata T
Front Immunol; 2018; 9():820. PubMed ID: 29725338
[TBL] [Abstract][Full Text] [Related]
19. SAP binds to CD22 and regulates B cell inhibitory signaling and calcium flux.
Ostrakhovitch EA; Wang Y; Li SS
Cell Signal; 2009 Apr; 21(4):540-50. PubMed ID: 19150402
[TBL] [Abstract][Full Text] [Related]
20. Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties.
Carnahan J; Wang P; Kendall R; Chen C; Hu S; Boone T; Juan T; Talvenheimo J; Montestruque S; Sun J; Elliott G; Thomas J; Ferbas J; Kern B; Briddell R; Leonard JP; Cesano A
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3982S-90S. PubMed ID: 14506197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
